IMUNON's Phase 3 ovarian cancer trial cleared to continue by safety panel
Tweet Send to a Friend
IMUNON, Inc. (Nasdaq: IMNN) announced that an independent Data Monitoring Committee has recommended continuation of its Phase 3 OVATION 3 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
